Drug Profile
Research programme: glycogen synthase kinase-3 inhibitors - Eli Lilly and Company
Alternative Names: 603281-31-8; LY-GSK-3iLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Azepines; Indoles; Pyrroles; Small molecules
- Mechanism of Action Apoprotein stimulants; Cell cycle modulators; Glycogen synthase kinase 3 inhibitors; Osteogenesis stimulants; Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Muscular atrophy; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in USA
- 20 Apr 2010 Pharmacodynamics data from preclinical trials in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research
- 14 Dec 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)